Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end

Cardiff Oncology, Inc.

2024-Q3 EPS reported -$0.74 revenue$532,000

Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.
Net cash used in operations: $10.5M in Q3 2024, up from $8.0M in Q3 2023.
Total operating expenses $12.8M for Q3 2024, an increase of $1.8M YoY.
Initial data readout from first-line RAS-mutated mCRC CRDF-004 trial expected by end of 2024.
Phase 2 trial in second-line KRAS-mutant mCRC published in Journal of Clinical Oncology; bev naïve patients had ORR 77% and mPFS 14.9 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.